Lyell Immunopharma Company Leadership
| LYEL Stock | USD 0.70 0.04 6.06% |
Lyell Immunopharma employs about 224 people. The company is managed by 14 executives with a total tenure of roughly 523 years, averaging almost 37.0 years of service per executive, having 16.0 employees per reported executive. Inspection of Lyell Immunopharma's management performance can provide insight into the company performance.
Lyell |
Lyell Immunopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.1912) % which means that it has lost $0.1912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3322) %, meaning that it created substantial loss on money invested by shareholders. Lyell Immunopharma's management efficiency ratios could be used to measure how well Lyell Immunopharma manages its routine affairs as well as how well it operates its assets and liabilities.Lyell Immunopharma Workforce Comparison
Lyell Immunopharma is rated fourth overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,055. Lyell Immunopharma holds roughly 224 in number of employees claiming about 7% of equities under Health Care industry.
Lyell Immunopharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lyell Immunopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lyell Immunopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lyell Immunopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lyell Immunopharma Notable Stakeholders
A Lyell Immunopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lyell Immunopharma often face trade-offs trying to please all of them. Lyell Immunopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lyell Immunopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lynn MD | CEO President | Profile | |
| Richard Goold | Chief Officer | Profile | |
| Ann Tomlin | Senior Resources | Profile | |
| Crystal MD | Founder Advisor | Profile | |
| Nellie Dillery | Director Accounting | Profile | |
| Matthew JD | Chief Officer | Profile | |
| Richard MD | Founder Chairman | Profile | |
| Elizabeth Homans | CEO Director | Profile | |
| Stephen Hill | Chief Officer | Profile | |
| Charles Newton | Chief Officer | Profile | |
| Prof MD | Founder Advisor | Profile | |
| Bryan Selby | Senior Operations | Profile | |
| Gary Lee | Chief Officer | Profile | |
| Ellen Rose | Senior Relations | Profile |
About Lyell Immunopharma Management Performance
The success or failure of an entity such as Lyell Immunopharma often depends on how effective the management is. Lyell Immunopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lyell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lyell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Lyell Immunopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 219 people.
Lyell Immunopharma Workforce Analysis
Traditionally, organizations such as Lyell Immunopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lyell Immunopharma within its industry.Lyell Immunopharma Manpower Efficiency
Return on Lyell Immunopharma Manpower
| Revenue Per Employee | 580 | |
| Revenue Per Executive | 9.3K | |
| Net Loss Per Employee | 1M | |
| Net Loss Per Executive | 16.8M | |
| Working Capital Per Employee | 2.3M | |
| Working Capital Per Executive | 37.2M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.